NAV-001 is a next-generation antibody-drug conjugate (ADC). NAV-001 targets and kills tumor cells that express mesothelin (MSLN) via release of its toxic payload (figure). We have discovered that HIO-1 (CA125) produced in the tumor microenvironment can diminish payload delivery inside the tumor cells. With this knowledge, we used our proprietary screening platforms to select an ADC that is refractory to HIO-1 and is more effective at killing MSLN-positive tumor cells. 
NAV-001 is being developed for advanced stage lung adenocarcinoma (mesothelin overexpressed in 54% of cases) and first-line mesothelioma (mesothelin over-expressed in 100% of epithelioid mesothelioma).